Press Releases
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Relmada Therapeutics to Present at Biotech Showcase 2019
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
